Fidelity Investments
MNPR icon

Fidelity Investments’s Monopar Therapeutics MNPR Stock Holding History

Fidelity Investments’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.1K Buy
530
+121
+30% +$7.49K ﹤0.01% 4314
2026
Q1 		$22.4K Buy
409
+51
+14% +$3.08K ﹤0.01% 4467
2025
Q4 		$23.4K Buy
358
+8
+2% +$654 ﹤0.01% 4408
2025
Q3 		$28.6K Buy
350
+319
+1,029% +$14.3K ﹤0.01% 4211
2025
Q2 		$1.11K Buy
+31
New +$1.13K ﹤0.01% 4951
2024
Q2 		– Sell
-1,100
Closed -$3.75K – 5537
2024
Q1 		$3.75K Buy
+1,100
New +$3.28K ﹤0.01% 4584
2023
Q3 		– Sell
-30
Closed -$128 – 5436
2023
Q2 		$128 Buy
+30
New +$153 ﹤0.01% 4943
2022
Q3 		– Sell
-2
Closed – – 5212
2022
Q2 		$0 Buy
+2
New +$23 ﹤0.01% 5276

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments's MNPR Position: Q2 2026 in Review

Fidelity Investments increased its Monopar Therapeutics (MNPR) stake by 30% in Q2 2026, buying an estimated $7.49K and bringing the position to 530 shares worth $49.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4314.

Fidelity Investments first reported a position in MNPR in Q2 2022 and has held it in 8 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Fidelity Investments held 530 shares of Monopar Therapeutics worth $49.1K as of Q2 2026.
  • Fidelity Investments bought 121 Monopar Therapeutics shares in Q2 2026, an estimated $7.49K.
  • Monopar Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4314 holding.
  • Fidelity Investments first reported a position in Monopar Therapeutics in Q2 2022 and has held it in 8 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.